Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911274 · ClinicalTrials.gov registry record · Phase 1
Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00911274: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00911274 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911274, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The objective of this study was to compare the oral bioavailability of an investigational formulation of mycophenolate mofetil (MMF) 250 mg capsules to an equivalent dose of the commercially available reference product, CellCept® (mycophenolate mofetil) 250 mg administered to healthy subjects following an overnight fast of at least 10 hours.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG CellCept®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-10 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911274
The ClinicalTrials.gov registry entry for NCT00911274 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00911274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00911274 about?
NCT00911274 is a clinical study titled "Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions". The objective of this study was to compare the oral bioavailability of an investigational formulation of mycophenolate mofetil (MMF) 250 mg capsules to an equivalent dose of the commercially available reference product, CellCept® (mycophenolate mofetil) 250 mg administered to healthy subjects follow...
What is the current status of trial NCT00911274?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2006-10. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00911274?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), CellCept® (DRUG).
Who is sponsoring clinical trial NCT00911274?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.